金吾财讯 | 和黄医药(00013)短线走高，截至发稿，涨2.74%，报24.72港元，成交额1.66亿港元。消息面上，1H25公司呋喹替尼海外销售额1.63亿美元，同比+25%，保持稳健增长。根据公司公告，截至1H25 呋喹替尼已经在超过30 个国家和地区获批上市，进一步扩大医保报销覆盖，提升市场份额。1H25 公司国内呋喹替尼、赛沃替尼和索凡替尼收入同比下滑，主要由于销售架构调整和竞争格局变化。中金认为，下半年得益于赛沃替尼新适应症获批和呋喹替尼海外放量顺利，公司产品销售收入趋势有望改善。
金吾财讯 | 和黄医药(00013)短线走高，截至发稿，涨2.74%，报24.72港元，成交额1.66亿港元。消息面上，1H25公司呋喹替尼海外销售额1.63亿美元，同比+25%，保持稳健增长。根据公司公告，截至1H25 呋喹替尼已经在超过30 个国家和地区获批上市，进一步扩大医保报销覆盖，提升市场份额。1H25 公司国内呋喹替尼、赛沃替尼和索凡替尼收入同比下滑，主要由于销售架构调整和竞争格局变化。中金认为，下半年得益于赛沃替尼新适应症获批和呋喹替尼海外放量顺利，公司产品销售收入趋势有望改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.